In HR+/HER2+ BC, a complex molecular bidirectional crosstalk between the ER and HER2 pathways may be crucial in affecting sensitivity to both HER2-targeted therapy and endocrine treatment [23,24,26]. The gene discussed is HR; the disease is breast cancer.